Meta-analysis links semaglutide and tirzepatide to fewer HFpEF worsening events

The wire

1. 01In NMCD, four studies met criteria and three randomized trials (n=1,876) were pooled: KCCQ-CSS rose 7.39 points, six-minute walk distance 17.18 m, and body weight fell 7.73%.
2. 02Clinicians managing obesity-related HFpEF now have pooled evidence supporting an adjunctive role for incretin therapy alongside standard care, with gastrointestinal intolerance the most common adverse event.
3. 03Heterogeneity for weight loss was high (I2 93%) and only three randomized trials were included; the authors call for larger, longer dedicated outcome trials.

From the source

The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis

Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Sep 8 · AlAraibi AJ, Shakeeb FN, Alqatta T et al.